NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00)
The NCI Predoctoral to Postdoctoral Fellow Transition (F99/K00) Award supports outstanding PhD and other research doctoral candidates complete their dissertation research training (F99 phase) and transition in a timely manner to mentored, cancer-focused postdoctoral career development research positions (K00 phase). Applicants for the F99 should be 3rd or 4th year graduate students nominated by their institutions.
- Students in years 3 or 4 of PhD graduate training only
- International students ARE eligible
- Current F31 awardees/applicants ARE eligible
Those interested in applying should send the following materials, compiled into a single PDF, as an email attachment to Jeff Mills at firstname.lastname@example.org by January 5, 2018:
- An NIH NRSA (F31) style Biosketch
- A short description of your research accomplishments thus far, plans for completion, and career goals including the area of planned emphasis in postdoctoral training
- A letter of nomination from your sponsor/mentor.
NCI Informational Webinar: Tuesday, December 5, 2017, 12:45 PM EST
Winship Internal Due Date: January 5, 2018
Full Application Due Date: February 21, 2018
Contact: Jeff Mills at email@example.com
Special Opportunity for Acral Melanoma ResearchThe Melanoma Research Alliance (MRA) is pleased to announce a Special Opportunity for Acral Melanoma Research. Both Team Science Award and Young Investigator Award proposals will be considered via this Request for Proposals (RFP).
Priority will be given to proposals that focus on NF1 loss, TERT promoter alterations, CCND1 and/or CRKL amplification. Research leading to therapeutic interventions and/or improved understanding of how these genetic alterations contribute to acral melanoma development and progression will be considered. Acral melanoma need not be the sole focus of the research, however, priority will be given to proposals that incorporate acral melanoma in at least one specific aim.
Initial Due Date (for proposal title, technical abstract, and list of team members): December 15, 2017
Proposal Due Date: January 9, 2018
Alex's Lemonade Stand - Epidemiology Grants
Alex’s Lemonade Stand Epidemiology Grants are $100,000 per year for two years. Funding allows investigators to pursue research studies in human populations, using epidemiological approaches, in order to significantly contribute to the understanding of childhood cancers. Hypothesis-driven research may focus on risk factors, early detection, prevention, effectiveness and treatment outcomes. Awards are $100,000 per year for two years.
Application Due Date: December 15, 2017
Pancreatic Cancer Action Network Grants
The Pancreatic Cancer Action Network offers grants for basic, translational and clinical research in pancreatic cancer to scientists and clinicians at various career levels.
2018 Catalyst Grant
Supports a junior faculty to conduct pancreatic cancer research and establish successful career paths in the field with a $500,000 grant over three years. Proposed research may be basic, translational, clinical or epidemiological in nature and must have direct applicability and relevance to pancreatic cancer.
Application Due Date: December 15, 2017
2018 Translational Research Grant
Supports independent investigators conducting high priority pancreatic cancer research that is poised for important translational next steps with a $500,000 grant over two years. Proposed research should aim to identify novel targets and approaches to the treatment of pancreatic cancer or understand and circumvent treatment resistance.
Application Due Date: January 15, 2018
Caspar Wistar Fellows Program
The Caspar Wistar Fellows Program will recruit two exceptional postdoctoral fellows as independent investigators, creating a springboard for the Caspar Wistar Fellows to facilitate a subsequent faculty appointment and join the next generation of scientific leaders. One Fellow with a cancer focus will be recruited to join Wistar’s NCI-designated Cancer Center and one Fellow with vaccine/immunology expertise will be recruited to join Wistar’s Vaccine & Immunotherapy Center.
Candidates whose work is based on biological principles, but incorporates concepts from diverse fields, are encouraged to apply. Candidates must hold a Ph.D., M.D., or equivalent degree. Candidates are expected to have a strong publication record.
Interested candidates should electronically submit the following to the attention of Maria Colelli, Search Coordinator Caspar Wistar Fellows Program:
- cover letter
- curriculum vitae
- a description of previous research (one page)
- a concise statement of research plans (up to two pages)
- reprints of four publications
- names of three references
NCI Clinical and Translational Exploratory/Developmental Studies (R21)
The National Cancer Institute has issued this funding opportunity to promote innovative pre-clinical, early-phase clinical, and correlative studies that are hypothesis-driven and based upon established basic cancer research discoveries. By using the R21 mechanism, this funding opportunity will support exploratory/developmental projects in the advancement of novel anti-cancer agents, diagnostic tools, and clinical approaches in treatment, symptom management, and prevention of common or rare tumors. These studies may involve considerable risk, but may lead to a breakthrough in a particular area, and/or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research (pre-clinical or clinical).
Application Due Date: February 20, 2018
Paul Calabresi Career Development Award for Clinical Oncology (K12)
This funding opportunity announcement encourages applications for institutional research career development (K12) programs from applicant organizations that propose to promote the training and career development of clinical trials researchers. It is intended to increase the number of clinicians (MDs, DOs, PharmDs, nurses with PhDs or equivalent) and non-clinician postdoctoral researchers trained to design and test clinical therapeutic research protocols in clinical trial settings (pilot/Phase I, Phase II, and Phase III clinical trials).Application Due Date: June 15, 2018
Oral Anticancer Agents: Utilization, Adherence, and Health Care Delivery
The Behavioral Research Program, Epidemiology and Genomics Research Program, and Healthcare Delivery Research Program of the National Cancer Institute’s Division of Cancer Control and Population Sciences have collaborated on the release of a program announcement to study the utilization, adherence, and delivery of oral anticancer agents. Specifically, this program announcement encourages research grant applications to:
- Assess and describe the current state of oral anticancer medication utilization, delivery, and adherence;
- Identify structural, systemic, and psychosocial barriers to adherence; and
- Develop models and strategies to improve safe and effective delivery of these agents so that clinical outcomes are optimized.